Eylea

EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results
EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results
BioSpace
Eyepoint
clinical trials
wet age-related macular degeneration
Eylea
EYP-1901
Flag link:
European regulator endorses high-dose version of Bayer eye drug Eylea
European regulator endorses high-dose version of Bayer eye drug Eylea
Reuters
Bayer
EMA
Eylea
Roche
Flag link:
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Regeneron
Eylea
Roche
Vabysmo
Flag link:
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Motley Fool
Novartis
biosimilars
Eylea
Flag link:
Regeneron Expands Eylea’s Label with High-Dose Approval
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Regeneron
Eylea
FDA
Flag link:
Sandoz plans to enter the Eylea biosimilar race
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Sandoz
generics
biosimilars
Eylea
Novartis
wet age-related macular degeneration
Flag link:
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Regeneron
Eylea
age-related macular degeneration
FDA
Flag link:
Regeneron expects FDA decision on higher-dose Eylea this year
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Regeneron
Eylea
FDA
Flag link:
Is Regeneron's Stock in Trouble After This FDA Rejection?
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Regeneron
Eylea
FDA
Flag link:
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Regeneron
Eylea
FDA
Flag link:
Roche’s new eye drug pressures Eylea with strong launch
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Roche
Vabysmo
Eylea
earnings
Regeneron
Flag link:
5 FDA decisions to watch in the second quarter
5 FDA decisions to watch in the second quarter
BioPharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Flag link:
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Fierce Pharma
Bayer
earnings
Eylea
Flag link:
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Regeneron
earnings
Eylea
Flag link:
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Flag link:
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Endpoints
Coherus Biosciences
biosimilars
ophthalmology
Eylea
Regeneron
Flag link:
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Flag link:
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Endpoints
Regeneron
Bayer
Eylea
pediatric exclusivity
biosimilars
Flag link:
Regeneron secures priority review for Eylea's use in infant retinopathy
Regeneron secures priority review for Eylea's use in infant retinopathy
Fierce Pharma
Eylea
Regeneron
retinopathy of prematurity
FDA
priority review
Flag link:
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Yahoo/Reuters
Bayer
Regeneron
Eylea
diabetic macular edema
wet age-related macular degeneration
Flag link:

Pages